Hereditary disease testing provider Variantyx has secured $41.5 million in funding in a round led by New Era Capital Partners. The company will use the funds to launch its precision oncology offerings, it said.
Variantyx is developing platforms for whole-genome sequencing and analysis that will allow healthcare providers to better understand the genetic makeup of patients. The company's products will use multiple genomic technologies to analyze and identify the genetic alterations in tumors, generating information that can help predict patient response to treatment.
Other investors in the round included Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, according to the firm.
